Tag
A large-scale retrospective cohort study demonstrates that 9-valent HPV vaccination in males aged 9-26 years is associated with a 46% reduction in HPV-related cancer risk. The findings support sex-neutral HPV vaccination strategies and high
A randomized trial of 20,330 girls 12–16 years shows one dose of bivalent or nonavalent HPV vaccine prevents persistent HPV16/18 infection as effectively as two doses over 5 years, with high effectiveness and no safety signals.
This study evaluates immune responses and HPV infection rates in Indian girls after receiving one, two, or three doses of the quadrivalent HPV vaccine, supporting WHO’s recommendation for two doses spaced at least six months apart.
PRIMAVERA immunobridging shows single-dose Cervarix induces near-universal seropositivity at 36 months and non-inferior HPV-18 antibodies versus three-dose Gardasil-4, but HPV-16 antibody GMCs were lower; results inform but do not yet suppo
Seventeen years after HPV vaccine introduction, substantial reductions in vaccine-type HPV prevalence confirm strong effectiveness and herd protection among vaccinated and unvaccinated sexually experienced adolescent girls and young women a
HPV-related oropharyngeal cancer incidence has surpassed cervical cancer, with men facing a 5-10 fold higher risk. Understanding this shift, symptoms, risks, and the critical role of HPV vaccination can transform prevention and early detect
This systematic review reveals multifaceted barriers to HPV vaccine uptake among migrants globally, with overall low coverage. It highlights individual, social, and systemic factors influencing uptake and delineates effective culturally tai
